Citations

Clear

959 citation(s) found for "Service, F J".

Masters athletes with abnormal cardiovascular findings: a clinical consensus statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology
Eijsvogels, Thijs M H , Kim, Jonathan H. , Aengevaeren, Vincent L. , D’Ascenzi, Flavio , Churchill, Tim, Dineen, Elizabeth H. , Garza, M Sanz-De La, Gati, Sabiha , Hálasz, Géza , Haugaa, Kristina H. , Heidbüchel, Hein , Lampert, Robin, Krishnan, Sheela , Maestrini, V, Martinez, Matthew, Phelan, Dermot , Thompson, Paul D. , Churchill, Timothy W. , Churchill, Timothy W , Sanz-de la Garza, María , Haugaa, Kristina , La Gerche, Andre , Lampert, Rachel , Krishnan, Sheela , Maestrini, Viviana , Papadakis, Michael , Perone, Francesco , Phelan, Dermot , Sharma, Sanjay , Thompson, Paul D , Baggish, Aaron L , Claessen, Guido , Eijsvogels, Thijs M.H. , Gerche, André La , Martinez, Matthew W. , Perone, Francesco , Baggish, Aaron L.

Mayo Clinic

European Heart Journal | January 16, 2026 | Volume: 47 | Issue: 21 | Pages: 2541-2560

10.1093/eurheartj/ehag040 | PMID 41947397 Get It

Abstract Exercise training improves cardiovascular health and reduces the risk for future cardiovascular events and mortality. However, emerging evidence suggests that Masters athletes may have a higher prevalence of cardiovascular abnormalities, such as atrial arrhythmias, coronary atherosclerosis, aortic dilatation, and myocardial fibrosis, compared to their less active peers. The clinical management of Masters athletes may be challenging as available guidelines for such conditions are generally based on data derived from symptomatic sedentary patients, limiting their applicability to highly trained individuals. Other unique challenges in the clinical assessment of Masters athletes include differences in symptomatic presentations compared to sedentary individuals, potential resistance to the initiation of pharmacologic treatment, and the increasing availability of consumer wearable health data that may provide relevant information on their cardiovascular health status. The purpose of this joint EAPC/ESC and ACC Clinical Consensus Statement is to provide an in-depth update on the current state of knowledge on abnormal cardiovascular findings in Masters athletes. We present an expert-based approach on the diagnostic assessment, management, and prognosis of (i) atrial fibrillation, (ii) bradyarrhythmias, (iii) ventricular arrhythmias, (iv) coronary atherosclerosis, (v) aortic dilatation, (vi) myocardial fibrosis, and (vii) exercise-induced arrhythmogenic cardiomyopathy. Clinical challenges, areas of ongoing controversy, and uncertainty and the potential underlying mechanisms are discussed. We also present future perspectives and research directives to further refine current best practice strategies. This includes the need for clinical outcome studies, dedicated randomized controlled trials in athletes, and international registries with diverse populations and longitudinal follow-up to evaluate the natural history of cardiac abnormalities and facilitate development of evidence-based approaches in the clinical management of Masters athletes with cardiovascular abnormalities.
Reference Handbook of Gynecologic Pelvic MRI
Alexander, Lauren F. , Patel-Lippmann, Krupa , Venkatesan, Aradhana M. , Causa-Andrieu, Pamela, Feldman, Myra K., Desai, Madhura , Law, Wyanne , Mansoori, Bahar , Nicola, Refky, Andrieu, Pamela Causa , Nougaret, Stephanie , Patel-Lippmann, Krupa , Venkatesan, Aradhana M , Causa Andrieu, Pamela , Feldman, Myra , Desai, Madhura A , Mansoori, Bahar , Nicola, Refky , Sadowski, Elizabeth A , Lakhman, Yulia , Alexander, Lauren F , Nougaret, Stéphanie , Feldman, Myra , Sadowski, Elizabeth A. , Lakhman, Yulia

Mayo Clinic

RadioGraphics | January 8, 2026 | Volume: 46 | Issue: 2 | Pages: No page available

10.1148/rg.250029 | PMID 41505283 Get It

The interpretation of gynecologic pelvic MRI benefits from tailored MRI protocols, radiologists' knowledge of normal female pelvic anatomy, and a step-by-step approach focusing on lesion origin, lesion tissue composition, and solid tissue morphology, with findings presented in a structured report.
POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia
Zanwar, Saurabh , Abeykoon, Jithma P. , D'Sa, Shirley , Larson, Dirk R. , Colby, Colin , Durot, Eric, Kastritis, Efstathios, Uppal, Encarl , Tomkins, Oliver , Morel, Pierre , Montes, Lydia , Paludo, Jonas, Ogunbiyi, Olabisi, Cornillet‐Lefèbvre, Pascale , Rajkumar, S Vincent, Quinquenel, Anne, Gertz, Morie A, Kumar, Shaji , Dimopoulos, M, Ansell, Stephen M., Kapoor, Prashant , D’Sa, Shirley , Abeykoon, Jithma P , Roos-Weil, Damien , Larson, Dirk , Colby, Colin L , Durot, Eric , Kastritis, Efstathios , Uppal, Encarl , Tomkins, Oliver , Morel, Pierre , Mondello, Patrizia , Montes, Lydia , Paludo, Jonas , Ogunbiyi, Olabisi , Cornillet-Lefebvre, Pascale , Quinquenel, Anne , Dispenzieri, Angela , Fonseca, Rafael , Gertz, Morie A , Kumar, Shaji K , Dimopoulos, Meletios A , Treon, Steven , Castillo, Jorge J , Kapoor, Prashant , Durot, Éric , Kastritis, Efstathios , Mondello, Patrizia , Paludo, Jonas , Ailawadhi, Sikander , Sarosiek, Shayna , Rajkumar, S. Vincent , Quinquenel, Anne , Dispenzieri, Angela , Fonseca, Rafaël , Gertz, Morie A. , Dimopoulos, Meletios Α. , Ansell, Stephen M. , Treon, Steven P. , Castillo, Jorge J.

Mayo Clinic

Blood Advances | January 7, 2026 | Volume: 10 | Issue: 7 | Pages: 2322-2327

10.1182/bloodadvances.2025017751 | PMID 41499755 Get It

Abstract Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 and CXCR4 mutations, whose prognostic value in patients treated with chemoimmunotherapy remains unclear. Moreover, the typically prolonged progression-free survival (PFS) correlates inconsistently with overall survival (OS), underscoring the importance of examining other surrogates. Progression of disease within 24 months (POD24), an established early end point, delineates functionally high-risk patients in other indolent lymphomas. This international study evaluated 253 patients receiving frontline fixed-duration bendamustine-rituximab (BR), a common chemoimmunotherapy for WM. At a median follow-up of 5.9 years, 5-year PFS and OS were 65% and 87%, respectively; 5-year PFS was similar between MYD88L265P (90%) and MYD88wild-type (WT) subcohorts (64% each; P = .4). Among 89 patients with known CXCR4 status, the subcohort with CXCR4mutation (28%) had shorter PFS (median 3.3 vs 8.8 years; hazard ratio [HR], 2.8; P = .0036) and OS (HR, 2.6; P = .036) compared with CXCR4WT. POD24 occurred in 11.5% of patients who demonstrated inferior subsequent OS (5-year OS, 71% vs 86%; HR, 3.1; P = .005) and higher mortality (standardized mortality ratio [SMR], 3.7), unlike the non-POD24 group, whose mortality was comparable to the matched general population (SMR, 1.1). In conclusion, BR is effective irrespective of the MYD88 status, but CXCR4 mutations and POD24 portend worse outcomes. Patients without POD24 represent a cohort with distinctly favorable outcome.
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)( CCND1 ; IGH )
Wiedmeier-Nutor, Julia Erin, Jelinek, Tomas, Shivaram, Suganti, Tang, Hongwei , Owens, Rebecca W, Tereza, Ševčíková, Fonseca, Rodrigo , Zhao, Logan, Zhu, Yuan Xiao, Matulis, Shannon M. , Mitsiades, C., Hajek, R, Chesi, M., Bergsagel, P. Leif, Esteban, Braggio, Kumar, Shaji , Wiedmeier, Julia E. , Wiedmeier-Nutor, J Erin, Fonseca, Rodrigo , Durante, Michael , Diamond, Benjamin T , Zhu, Yuan X , Landgren, C Ola , Chesi, Marta , Bergsagel, P. Leif , Braggio, Esteban , Boise, Lawrence H , Fonseca, Rafael , Kumar, Shaji K , Maura, Francesco , Wiedmeier-Nutor, Julia E , Kaddoura, Marcella , Gupta, Vikas A. , Ziccheddu, Bachisio , Shivaram, Suganti, Sevcikova, Tereza, Durante, Michael , Diamond, Benjamin , Shi, Chang-Xin , Mitsiades, Constantine S. , Landgren, Ola , Usmani, Saad Z. , Hájek, Roman , Chesi, Marta , Bergsagel, P. Leif , Braggio, Esteban , Boise, Lawrence , Fonseca, Rafaël , Maura, Francesco , Baughn, Linda B.

Mayo Clinic

Blood | January 2, 2026 | Volume: 147 | Issue: 14 | Pages: 1598-1610

10.1182/blood.2025029996 | PMID 41481388 Get It

Abstract Multiple myeloma (MM) with t(11;14)(CCND1;IGH) remains the only subset sensitive to the BCL2 inhibitor venetoclax. However, not all patients with t(11;14)(CCND1;IGH) respond to treatment, and some progress early after initial response. To investigate this, we examined 44 whole-genome and whole-exome sequencing data samples from 34 patients with t(11;14) MM treated with venetoclax. The presence of mutations in the RAS pathway was strongly associated with shortened progression-free survival (PFS) and was validated in an independent cohort of 21 patients with MM. The presence of 1q gain was also associated with shorter PFS in patients without RAS mutations. In 10 patients with paired prevenetoclax and postvenetoclax treatment samples, postvenetoclax progression was recurrently driven by the selection of genomic events in the BCL2/MCL1 and RAS pathways and of high-risk features (eg, loss of TP53 and CDKN2C). Overall, our study shows that comprehensive genomic profiling can identify most mechanisms underlying resistance to BCL2 inhibition in t(11;14)(CCND1;IGH) MM.
Palliative Surgery Versus Conservative Management for Patients With Bowel Obstruction and Unresectable Peritoneal Carcinomatosis Referred to a Colon and Rectal Surgery Service in a Quaternary Referral Center
Reynolds, Ian S. , Narasimhan, Avantika Lakshmi, Bews, Katherine A. , Mathis, Kellie L. , Reynolds, Ian S , Narasimhan, Avantika Lakshmi , Larson, David W. , McKenna, Nicholas P.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | December 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10499091251411855 | PMID 41424227 Get It

Background Bowel obstruction in the setting of peritoneal metastases is a complex clinical situation. Evidence for operative intervention in this setting remains unclear. This study aimed to compare outcomes between patients with bowel obstruction and peritoneal metastases who underwent operative intervention vs those who underwent conservative management. Methods This was a retrospective single center study of all patients that were consulted on by the Division of Colon and Rectal Surgery in the 6-year period between January 1st 2019 and December 31st 2024 for the management of bowel obstruction in the setting of peritoneal metastases. The study compared patients who underwent operative intervention vs those who underwent conservative management. The primary outcome measures were ability to tolerate solid food at discharge, median obstruction free survival, and median overall survival. Results A total of 100 patients were diagnosed with bowel obstruction in the setting of peritoneal carcinomatosis. 47 patients underwent operative intervention and 53 underwent non-operative management. Those who underwent operative intervention were more likely to tolerate solid food at discharge (78.72% vs 47.17%, P < 0.01) and had a longer median obstruction free survival (593 days vs 147 days, P = 0.01). No difference was identified in overall survival (133 days vs 99 days, P = 0.49). Conclusions Bowel obstruction in the setting of peritoneal metastases is a complex situation that requires a personalized and pragmatic approach for each patient. Selecting those who may benefit from operative intervention can be challenging, however, there are subsets of patients for whom surgical management may be offered with acceptable outcomes.
Turncoat antibodies unmasked in a model of autoimmune demyelination: From biology to therapy
Taghipour-Mirakmahaleh, Reza , Morin, Françoise , Zhang, Yu , Bourhoven, Louis , Béland, Louis‐Charles , Zhou, Qun , Park, Anna , Corbeil, Jacques , Marignier, Romain , Larochelle, Catherine , Jaworski, Julie , Park, Anna , Corbeil, Jacques , Marignier, Romain , Larochelle, Catherine , Kerfoot, Steven M , Vallières, Luc , Dominguez, Juan Manuel, Flanagan, Eoin P.

Mayo Clinic

Proceedings of the National Academy of Sciences | December 17, 2025 | Volume: 122 | Issue: 51 | Pages: No page available

10.1073/pnas.2424988122 | PMID 41405856 Get It

Autoantibodies contribute to many autoimmune diseases, yet there is no approved therapy to neutralize them selectively. A popular mouse model, experimental autoimmune encephalomyelitis (EAE), could serve to develop such a therapy, provided we can better understand the nature and importance of the autoantibodies involved. Here, we report the finding of autoantibody-secreting extrafollicular plasmablasts in EAE induced with specific myelin oligodendrocyte glycoprotein (MOG) antigens. Single-cell RNA sequencing reveals that these cells produce nonaffinity-matured IgG antibodies. These include pathogenic antibodies competing for shared binding space on MOG’s extracellular domain. Interestingly, the synthetic anti-MOG antibody 8-18C5 can prevent the binding of pathogenic antibodies from either EAE mice or people with MOG antibody disease. Moreover, an 8-18C5 variant carrying the NNAS mutation, which inactivates its effector functions, can reduce EAE severity and promote functional recovery. In brief, this study provides not only a comprehensive characterization of the humoral response in EAE models but also a proof of concept for a therapy to antagonize pathogenic anti-MOG antibodies.
Reduction of Erroneous ST-segment Elevation Myocardial Infarction Diagnoses
Klassen, Aaron B. , Chesney, Julie A., Wilson, Marcia J., Eastman, Susan C., Connelly, Rebecca A., Konz, Brent A, Bartelt, Jennifer M., Ring, Michael T, Winkel, Daniel, Churchill, Jason T, Griffin, Dawn M., Brady, Brian J., Bartelt, J., Johnson, Matthew P. , Gulati, Rajiv , Bennett, Courtney , Barsness, Gregory W. , Bartelt, Jason D, Wiley, Brandon, Porter, John L. , Chesney, Julie A., Wilson, Marcia J., Eastman, Susan C., Fatema, Kaniz , Connelly, Rebecca A., Winkel, Daniel B., Griffin, Dawn M., Brady, Brian J., Bartelt, Jason D., Wiley, Brandon M.

Mayo Clinic

CIN: Computers, Informatics, Nursing | December 17, 2025 | Volume: 44 | Issue: 2 | Pages: No page available

10.1097/cin.0000000000001379 | PMID 41371987 Get It

An ST-segment elevation myocardial infarction is a life-threatening condition within the spectrum of acute coronary syndrome, with well-recognized implications for short-term and long-term health outcomes. Retrospective review of our institutional electronic health records identified patterns of inaccurate acute coronary syndrome diagnostic assignment, including the presence of erroneous ST-segment elevation myocardial infarction diagnoses in discharge records. Such erroneous diagnoses in the durable health record may increase risk to patients through inadequate risk assessment and inappropriate follow-up care. Misapplication of a shortcut in our electronic health record system for rapidly ordering emergent cases was identified as a potential cause of the quality gap. To address this issue, a nurse-led quality improvement project was developed by using the define, measure, analyze, improve, and control framework. The project intervention decreased the percentage of patients with erroneous diagnoses from 24% to 7% and marginally improved nursing staff satisfaction. Our project successfully addressed an institutional quality concern. Our goal of reducing erroneous discharge diagnoses with minimal disruption to our existing practice was achieved, positively affecting our patients. Including both nurse leaders and frontline health care workers ensured the success of our project.
Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
Freeman, Ciara L. , Garcés, Juan-José, Lee, Holly , Papadimitriou, Marios , Silva, Ariosto Siqueira , Füller, Etta Rozen , Agius, Phaedra , Hansen, Doris K., Zhao, Xiaohong , Meads, Mark B. , Teer, Jamie K. , Hagner, Patrick R. , Alsina, Melissa , Ramasubramanian, Anusuya , Smith, Eric L. , Mailankody, Sham , Chesi, Marta, Hamadeh, Issam S. , Shain, Kenneth H. , Ilundain, Marta Larrayoz , Durante, Michael , Sharik, Meaghen E. , Du, Megan T. , Hagner, Patrick, Bergsagel, P. Leif , Landgren, C Ola , Maura, Francesco , Maclachlan, Kylee , Larráyoz, Marta , Ziccheddu, Bachisio , Meermeier, Erin W. , Garcés, Juan‐José , Durante, Michael , Firestone, Ross , Menges, Meghan A. , Reid, Kayla M. , Diamond, Benjamin , Sudalagunta, Praneeth Reddy , Leblay, Noémie , Ahn, Sungwoo , Fuller, Ethan, Briercheck, Edward L. , Hansen, Doris K. , Song, Xiaofei , Jelı́nek, Tomáš , Baz, Rachid , Smith, Eric, Giralt, Sergio , Bergsagel, P. Leif , Neri, Paola , Chesi, Marta , Martinez‐Climent, José A. , Locke, Frederick L. , Bahlis, Nizar Jacques , Landgren, Ola , Usmani, Saad Z.

Mayo Clinic

No container title available | December 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.08.692978 | PMID 41415462 Get It

ABSTRACT Chimeric antigen receptor T-cell (CART) and T-cell engager (TCE) therapies targeting B-cell maturation antigen (BCMA) are transforming the treatment landscape for relapsed multiple myeloma (MM). However, despite impressive initial response rates, most patients eventually relapse. To investigate this unmet medical need, we applied whole-genome sequencing (WGS) to MM cells from cohorts of 102 relapsed patients treated with anti-BCMA CART and TCE therapies. Several genomic alterations were associated with clinical outcomes, particularly primary refractoriness, including high genomic complexity and mutations in genes regulating plasma cell identity, which predicted resistance to therapy. Single-cell RNA sequencing further revealed that MM cells from refractory patients exhibited high proliferation signatures and reduced expression of TNFRSF17 (encoding BCMA), while were less enriched for plasma cell–associated transcriptional programs, a phenomenon we term “plasma cell identity escape.” This profile was strongly associated with immune dysregulation of CD8 T cells including increased activation and exhaustion. This evolution of MM toward a more proliferative and lineage-divergent state, refractory to the anti-BCMA T-cell redirecting therapies, was functionally validated in preclinical MM mouse models. Collectively, our results comprehensively define the cellular and molecular mechanisms underlying primary resistance to anti-BCMA therapies.
Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
Leaf, Rebecca Karp , Mones, Jodi V. , Shenoy, Tushar , Warsame, Mohamed , Moreira, Marina Beltrami , Panch, Sandhya , Leavitt, Andrew D., Zon, Rebecca L. , Shahamatdar, Sahar , Lim, Tristan , Cui, Can , Jiang, Debbie , Kaunfer, Sarah Allison , Durai, Lavanya , Hoge, Steven T., Dias, Julie‐Alexia , Sha, Carrie , Holmes, Aaron , Easton, Neil , Corley, Elizabeth M. , Zhao, Ethan, Li, Xingyi , Spelman, Amy, Amos, Christina Briggs, Soebbing, Doris, Shabih, Maria, Jamison, Trevor , Liu, Bolun , Hussein, Guleid , Yadav, Sumeet K. , Meara, Alexa, Juras, Patrick K. , Heskel, Marina, Reynolds, Kerry L. , Kroll, Michael H. , Leaf, David E. , Leaf, Rebecca K , Beltrami-Moreira, Marina , Cui, Can , Jiang, Debbie , Kaunfer, Sarah A , Durai, Lavanya , Dias, Julie-Alexia , Holmes, Aaron N , Easton, Neela , Corley, Elizabeth M , Liu, Bolun , Yadav, Sumeet Kumar , Elsaid, Mohamed I , Suresh, Arvind , Huang, Jennifer J , Glezerman, Ilya G , Al-Samkari, Hanny , Kroll, Michael H , Leaf, David E , Leavitt, Andrew D. , Kendall, Ellen K. , Hoge, Steven T., Li, Xingyi, Amos, Christina Briggs, Owen, Dwight H , Meara, Alexa, Go, Ronald S. , Al‐Samkari, Hanny

Mayo Clinic

Blood | December 8, 2025 | Volume: 147 | Issue: 12 | Pages: 1351-1364

10.1182/blood.2025031449 | PMID 41359796 Get It

Abstract Immune checkpoint inhibitor–associated immune thrombocytopenia (ICI-ITP) has been described in case reports and small case series, but comprehensive data on its incidence, risk factors, clinical features, treatment, and outcomes are lacking. We reviewed medical records of all adults initiating ICI therapy between 2016 and 2023 at 29 US hospitals across 7 major cancer centers to identify patients with ICI-ITP. Multivariable logistic regression was used to identify risk factors, and Cox modeling was performed to assess the association between ICI-ITP, its severity, and mortality. Among 86 467 patients, ICI-ITP occurred in 214 (0.25%). Independent risk factors included lower baseline platelet count, combination ICI therapy, stage IV cancer, and additional immune-related adverse events. ICI-ITP occurred at a median of 8 weeks (interquartile range [IQR], 4-18) after ICI initiation, with a median nadir platelet count of 41 × 109/L (IQR, 17 × 109/L to 64 × 109/L). Patients were treated with glucocorticoids (n = 106 [49.5%]), immune globulin (n = 39 [18.2%]), and thrombopoietin receptor agonists (n = 29 [13.6%]). Recovery occurred in 161 patients (75.2%) at a median of 2.3 weeks (IQR, 1.0-5.3). Of 76 patients rechallenged with ICIs, 23 (30.3%) developed recurrent ICI-ITP. ICI-ITP and its severity were associated with higher all-cause mortality, with a nearly threefold increase in risk among patients with severe ICI-ITP than those without ICI-ITP (adjusted hazard ratio, 2.96 [95% confidence interval, 2.14-4.08]). These findings establish ICI-ITP as a rare but clinically significant complication of ICI therapy, provide, to our knowledge, the first large-scale description of its risk factors and clinical course, and underscore the importance of timely recognition and management.